Patents by Inventor Hans-Georg Lerchen

Hans-Georg Lerchen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220016258
    Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
    Type: Application
    Filed: September 1, 2021
    Publication date: January 20, 2022
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
  • Publication number: 20210386864
    Abstract: The present invention relates to novel pharmaceutical compounds comprising of an ?v?3 integrin antagonist, a linking unit comprising of L-Val-L-Pro-L-Asp cleavable by elastase, a polyethyleneglycol (PEG) spacer and a cytotoxic element, to processes for preparation thereof, to the use thereof for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: October 30, 2019
    Publication date: December 16, 2021
    Inventors: Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Charlotte Christine KOPITZ, Jörg KELDENICH
  • Patent number: 11123439
    Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: September 21, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Leo Marx, Beatrix Stelte-Ludwig, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt
  • Publication number: 20210275686
    Abstract: The invention relates to a new binder-drug conjugates with improved properties, to active metabolites of said ADCs and to processes for the preparation thereof. The invention particularly relates to antibody-drug conjugates (ADCs) with CXCR5 antibodies and selected KSP inhibitors. The present invention further relates to the use of said conjugates for the treatment and/ore prevention of diseases and to the use of said conjugates for the production of medicaments for the treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases.
    Type: Application
    Filed: June 13, 2019
    Publication date: September 9, 2021
    Inventors: Sarah Anna Liesa JOHANNES, Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Pascale LEJEUNE, Hannah JÖRISSEN, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Stefanie HAMMER
  • Publication number: 20210252161
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 19, 2021
    Inventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
  • Publication number: 20210230284
    Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 29, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
  • Patent number: 11071788
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 27, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
  • Patent number: 11001636
    Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: May 11, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Christoph Mahlert, Simone Greven, Stephan Märsch
  • Patent number: 10973923
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 13, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Christoph Mahlert, Anne-Sophie Rebstock, Simone Greven, Nils Griebenow, Jan Tebbe, Oliver Kensch
  • Patent number: 10744205
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: August 18, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Christoph Mahlert, Simone Greven, Stephan Märsch, Dennis Kirchhoff
  • Publication number: 20200138970
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: May 7, 2020
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
  • Publication number: 20190365916
    Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
  • Patent number: 10485880
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 26, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Sven Wittrock, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Anne-Sophie Rebstock, Carsten Terjung, Simone Greven
  • Publication number: 20190351066
    Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 21, 2019
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Hannah JOERISSEN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER
  • Publication number: 20190328897
    Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 31, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
  • Publication number: 20190330357
    Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 31, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
  • Publication number: 20190262463
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: August 29, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
  • Patent number: 10350206
    Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: July 16, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Anne Mengel, Hans-Georg Lerchen, Manfred Möwes, Thomas Müller, Lars Bärfacker, Marion Hitchcock, Arwed Cleve, Joachim Kuhnke, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Ursula Mönning, Simon Holton
  • Publication number: 20190077752
    Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.
    Type: Application
    Filed: March 21, 2017
    Publication date: March 14, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Carsten TERJUNG, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT
  • Publication number: 20180318438
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: November 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Stephan MÄRSCH, Uwe GRITZAN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT, Lisa DIETZ